A practical reference on GW501516: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-23. Anything still debated is marked as such rather than presented as settled.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
With the development of X-ray crystallography, it became possible to determine protein structures as well as their sequences. The first protein structures to be solved were hemoglobin by Max Perutz and myoglobin by John Kendrew, in 1958. The use of computers and increasing computing power has supported the sequencing of complex proteins. In 1999, Roger Kornberg sequenced the highly complex structure of RNA polymerase using high intensity X-rays from synchrotrons. Since then, cryo-electron microscopy (cryo-EM) of large macromolecular assemblies has been developed. Cryo-EM uses protein samples that are frozen rather than crystals, and beams of electrons rather than X-rays. It causes less damage to the sample, allowing scientists to obtain more information and analyze larger structures. Computational protein structure prediction of small protein structural domains has helped researchers to approach atomic-level resolution of protein structures. As of April 2024, the Protein Data Bank contains 181,018 X-ray, 19,809 EM and 12,697 NMR protein structures.
=== 20th century === By the early 20th century, when Robert Falcon Scott made his first expedition to the Antarctic (1901–1904), the prevailing theory was that scurvy was caused by "ptomaine poisoning", particularly in tinned meat. However, Scott discovered that a diet of fresh meat from Antarctic seals cured scurvy before any fatalities occurred. But while he saw fresh meat as a cure for scurvy, he remained confused about its underlying causes. In 1907, an animal model that would eventually help to isolate and identify the "antiscorbutic factor" was discovered. Axel Holst and Theodor Frølich, two Norwegian physicians studying shipboard beriberi contracted by ship's crews in the Norwegian Fishing Fleet, wanted a small test mammal to substitute for the pigeons then used in beriberi research. They fed guinea pigs their test diet of grains and flour, which had earlier produced beriberi in their pigeons, and were surprised when classic scurvy resulted instead. This was a serendipitous choice of animal. Until that time, scurvy had not been observed in any organism apart from humans and had been considered an exclusively human disease. Certain birds, mammals, and fish are susceptible to scurvy, but pigeons are unaffected since they can synthesize ascorbic acid internally. Holst and Frølich found they could cure scurvy in guinea pigs with the addition of various fresh foods and extracts.
The analogous Xe complex, with an infrared signal at 1943 cm−1, was more stable and could be observed at −30 °C (243 K) in pressurized liquid Xe. The highly reactive and transient Cp*Rh(CO) species believed to form upon photolysis also coordinates to and inserts into the C–H bonds of cyclohexane and other alkanes (R–H) under these conditions to give alkane σ-complexes Cp*Rh(CO)(R–H) and rhodium(III) alkyl complexes Cp*Rh(CO)(R)(H) upon oxidative addition.
Sources: en.wikipedia.org
=== Trials of drugs === Some clinical trials involve healthy subjects with no pre-existing medical conditions. Other clinical trials pertain to people with specific health conditions who are willing to try an experimental treatment. Pilot experiments are conducted to gain insights for design of the clinical trial to follow. There are two goals to testing medical treatments: to learn whether they work well enough, called "efficacy", or "effectiveness"; and to learn whether they are safe enough, called "safety". Neither is an absolute criterion; both safety and efficacy are evaluated relative to how the treatment is intended to be used, what other treatments are available, and the severity of the disease or condition. The benefits must outweigh the risks. For example, many drugs to treat cancer have severe side effects that would not be acceptable for an over-the-counter pain medication, yet the cancer drugs have been approved since they are used under a physician's care and are used for a life-threatening condition. In the US the elderly constitute 14% of the population, while they consume over one-third of drugs. People over 55 (or a similar cutoff age) are often excluded from trials because their greater health issues and drug use complicate data interpretation, and because they have different physiological capacity than younger people. Children and people with unrelated medical conditions are also frequently excluded. Pregnant women are often excluded due to potential risks to the fetus.
=== DMPK, ADME, and bioanalysis === BioDuro conducts in vitro ADME assays, in vivo PK/TK studies, metabolic stability studies, and bioanalytical method development using LC–MS/MS platforms. These services are used to characterize compound absorption, distribution, metabolism, and excretion profiles during preclinical development.
==== Pregnancy and breastfeeding ==== There are no adequate and well-controlled studies of the naloxone's use in pregnant women, much of the information on naloxone in pregnancy comes from studies on the use of naloxone and buprenorphine together, rather than the study of naloxone on its own. Although one study showed a possible link to preterm labor and low birth weight, but once again this study was done on women with opioid use disorder who were taking Suboxone, no studies have been done to see if treatment with naloxone for an opioid overdose can increase the chance of pregnancy-related problems. Naloxone is able to cross the placental barrier and may precipitate neonatal withdrawal, as such it is important for women taking opioids during pregnancy to inform their baby's healthcare providers so that they can check for symptoms of withdrawal, especially if they are taking medications for OUD. Small amounts of naloxone are excreted in breast milk, however, as naloxone is poorly absorbed orally it is not orally bioavailable and therefore is unlikely to affect a breastfeeding infant.
6 July – BBC News reports that Reform UK would be highly unlikely to introduce an insurance based healthcare system in Wales should it win the 2026 Senedd election, largely because of the timescale and potential legal implications of doing so. 7 July – David Jones, a former Conservative Secretary of State for Wales who stepped down from Parliament at the 2024 election, announces he is defecting to Reform UK. Amazon removes a number of AI-generated unofficial biographies of Scotland's first ministers from sale after BBC News alerts them to a significant number of inaccuracies contained within the books. 8 July – French President Emmanuel Macron begins a three-day state visit to the UK, becoming the first French President to visit the UK since 2008, and the first European leader to do so since Brexit. Former prime minister Rishi Sunak joins Goldman Sachs as a senior advisor. James McMurdock says he will not return to Reform UK after asking to have the party whip withdrawn. Sir Robert Chote resigns as chairman of the UK Statistics Authority, the body that oversees the Office for National Statistics. MPs vote 415–98 to approve the Football Governance Bill that will establish a regulatory body for the top five tiers of English football. 9 July – Secretary of State for Wales Jo Stevens says public services in Wales will not face cuts despite a shortfall in covering a rise in employers' National Insurance contributions. Her comments follow a warning from Welsh Government Finance Secretary Mark Drakeford, who warned Wales was facing a £36m financial black hole.
Sources: en.wikipedia.org
== Structure == Disulfur difluoride has a chain structure F−S−S−F. The angle between the Fa−S−S and S−S−Fb planes is 87.9°, while the angles of Fa−S−S and S−S−Fb are equivalent, and are equal to 108.3°. Both S−F bonds are equivalent and their length is 163.5 pm, while the length of the S−S bond is 189 pm. This structure is referred to as gauche, and is similar to H2O2. There is a branched isomer of disulfur difluoride, thiothionyl fluoride, with the structure S=SF2.
== Structure == The inactive form of Limulus clotting enzyme, referred to as proclotting enzyme, consists of a single chain glycoprotein. The enzyme is activated upon cleavage at the Arg98-Ile99 bond by Limulus clotting factor B or Limulus clotting factor G. The active clotting enzyme consists of a light and heavy chain linked together by a disulfide bridge. The active site of the clotting enzyme is located in the heavy chain and contains the His-Asp-Ser catalytic triad that is common among serine proteases. The sequence of the heavy chain in the serine protease region is 34.1% homologous to that of human clotting factor X, and four disulfide linkages are found in the same locations in both enzymes (and in prothrombin). These similarities indicate a relationship between serine protease structure and function. Limulus clotting enzyme also has substrate specificity similar to mammalian factor X. The crystal structure of the enzyme is unknown. The enzyme’s light chain contains a clip-like disulfide-knotted structure. Sequence homology in this region to the precursor of serine protease easter in Drosophila suggests that this structure may be common in invertebrate serine protease zymogens. Structural similarity of the light chain clip domain to horseshoe crab defensin suggests that the clip domain may have some antimicrobial activity. The amino acid sequences of Limulus clotting enzyme and Limulus clotting factor B are 35.9% similar.
==== United Kingdom ==== During the 1980s, 7-Eleven convenience stores were based in London and the South East of England. The first shop opened in Hendon, north London in 1985. In October 1997 all 57 UK 7-Eleven stores were sold to Budgens. The company announced in 2014 they had planned to return to the UK market, but this did not progress beyond its announcement. In 2019, the company announced again it had planned to return, but as of October 2022 no stores had been opened.
=== Pain phase === Classically, a migraine headache occurs on one side and throbs with moderate to severe intensity. The throbbing is not in phase with the person's pulse. In around 40% of cases, the pain may affect both sides of the head. The pain phase usually lasts 4 to 72 hours in adults. Children and young people more often have shorter headaches with pain on both sides. Pain is frequently accompanied by nausea, vomiting, sensitivity to light, sensitivity to sound, sensitivity to smells, fatigue, and irritability. Many prefer a dark and quiet environment and seek to avoid stimuli to which they are sensitive. Nausea has been reported by almost 90% of people who self-report with migraine, and vomiting has been reported in from 28% to 70% of patients. Other symptoms may include blurred vision, symptoms affecting the sinuses and nasal passages such as nasal stuffiness, diarrhea, neck pain, and swelling or tenderness of the scalp. In rare cases called migraine with brainstem aura, neurological symptoms such as a sense of the world spinning, light-headedness, and confusion may affect both sides of the body. During the pain phase, motion and physical activity may increase pain. Migraineurs are likely to decrease physical activity during this time. However, the effects of physical activity on migraine are complex. Regular moderate exercise may reduce the frequency of migraine attacks.
Necrophages can be classified according to their nutritional reliance on carrion and also their level of adaptation to carrion feeding. Animals are described as 'obligate necrophages' if they use carrion as their sole or main food source and depend on carrion for survival or reproduction. The term 'specialists' is also sometimes used in recognition that these animals have traits favoring necrophagy and making other feeding behaviors difficult. For example, large wingspans facilitate the energy-efficient gliding vultures need to cover long distances in search of carrion, but reduce the agility needed to kill prey. Animals that eat carrion opportunistically and retain the traits needed to find and consume other food sources are described as 'facultative necrophages' and 'generalists'. Both obligate and facultative necrophages are sometimes sub-classified as 'wet' and 'dry' feeders. These terms differentiate animals feeding on moist, putrefying tissue from animals feeding on desiccated and keratinized tissues.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.